October 24, 2023
1 min watch
Save
VIDEO: ONL1204 demonstrates promising results in geographic atrophy
NEW YORK — In this Healio Video Perspective from OSN New York’s Disruptive Innovations Symposium, David Esposito, CEO of ONL Therapeutics, discusses results of ONL1204 in geographic atrophy.
“It’s a small peptide delivered via [intravitreal] injection, and we’re across three clinical programs: one in geographic atrophy, one in open-angle glaucoma and one in retinal detachment,” he said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Esposito reports being the CEO of ONL Therapeutics.
Read more about